GlassScriptPhysician profile
Margaret A Davis
NPI 1811989411
$1,977.43
in general payments reported to CMS, 2019-2025
31 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $288 · 2021: $462 · 2022: $263 · 2023: $340 · 2024: $286 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $735.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $210.54 | 2019-2023 | |
| Glaxosmithkline, LLC. | $192.15 | 2021-2024 | Bexsero, Shingrix, Arexvy |
| Lilly USA, LLC | $158.79 | 2020-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $153.81 | 2019-2024 | Airsupra |
| Corcept Therapeutics | $138.99 | 2019-2024 | Korlym |
| Novo Nordisk INC | $131.58 | 2019-2022 | |
| Celgene Corporation | $124.22 | 2023 | Pomalyst |
| Amarin Pharma, INC. | $101.72 | 2021-2022 | |
| Astellas Pharma US INC | $97.36 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $66.59 | 2022-2024 | Rexulti |
| Abbvie INC. | $64.35 | 2022 | |
| Inspire Medical Systems, INC. | $63.97 | 2025 | Inspire |
| Esperion Therapeutics, INC. | $52.73 | 2020-2021 | |
| Abbott Laboratories | $50.52 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.35 | 2021-2023 | Ofev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $38.16 | 2021-2022 | |
| Amgen INC. | $30.53 | 2020 | |
| Acadia Pharmaceuticals INC | $28.18 | 2025 | Nuplazid |
| Eisai INC. | $25.99 | 2020-2021 | |
| Edwards Lifesciences Corporation | $25.28 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.87 | 2019 | |
| Radius Health, INC. | $19.67 | 2024 | Tymlos |
| Jazz Pharmaceuticals INC. | $17.62 | 2022 | |
| Boston Scientific Corporation | $16.94 | 2025 | General - Pain Management |
| Emd Serono, INC. | $16.74 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.01 | 2020 | |
| Allergan, INC. | $13.93 | 2020 | |
| Ironshore Pharmaceuticals INC. | $13.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.13 | 2021 | |
| Daiichi Sankyo INC. | $11.87 | 2020 | |
| Medtronic, INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.